Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA 2.5?: Delay In FY 2003 FDA Appropriations Has PDUFA III In Limbo

Executive Summary

FDA is stalled in implementing portions of PDUFA III while it awaits Congressional approval of an appropriations bill for FY 2003
Advertisement

Related Content

FDA Defines Good Review Management; No Data In Labeling Negotiations
FDA Defines Good Review Management; No Data In Labeling Negotiations
FDA Hormone Therapy Outreach Campaign Urged By Congress In Budget
NDA Reviews To Be Studied Prospectively To Identify Best First-Cycle Practices
CBER/CDER Consolidation Receives McClellan’s Blessing; Tensions Continue
FDA Generic Biologics Policy May Be One Change Under McClellan
NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002
PDUFA III Implementation Begins: FDA Working Groups Under Way
PDUFA III Implementation Begins: FDA Working Groups Under Way
Ivax Generic Zoloft Exclusivity Will Be Unaffected By New FDA Guidance
Advertisement
UsernamePublicRestriction

Register

PS040776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel